Study guide
15.1 Endometriosis & Adenomyosis
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
15.1 Endometriosis & Adenomyosis
Key Takeaways Explain This Topic AI
Revised ASRM endometriosis stage reflects lesion distribution only and does not correlate with pain severity or disability.
Empiric medical therapy may be started without laparoscopy in a patient with a suggestive history, since a normal ultrasound does not exclude peritoneal disease.
GnRH agonist therapy requires mandatory norethindrone acetate 5 mg daily add-back to prevent bone loss and vasomotor symptoms.
Endometriosis produces a fixed retroverted uterus with tender uterosacral nodularity, while the adenomyotic uterus is symmetrically enlarged, boggy, and freely mobile.
A junctional zone of 12 mm or more on T2-weighted MRI is diagnostic of adenomyosis, and the 52 mg levonorgestrel IUD is the most effective medical treatment.
Last updated: September 2026
Benign pelvic conditions and urogynecologic disorders represent a substantial proportion of ambulatory gynecologic visits across the female lifespan. From debilitating cyclic pelvic pain and abnormal uterine bleeding to pelvic floor relaxation, urinary incontinence, and adnexal masses, these conditions profoundly impact physical comfort, emotional well-being, sexual function, and daily living. Certified nurse-midwives provide primary diagnostic evaluation, initiate evidence-based conservative and medical therapies, manage pessaries, and discern clinical red flags requiring collaborative surgical consultation or oncology referral.
Endometriosis: Pathophysiology, Presentation & Stepwise Management
Endometriosis is defined as the presence of functional endometrial glands and stroma outside the uterine cavity , predominantly located on pelvic peritoneum, ovaries, uterosacral ligaments, and the rectovaginal septum.
Pathophysiological Mechanisms
Retrograde Menstruation (Sampson's Theory): Transtubal reflux of viable desquamated menstrual endometrium into the peritoneal cavity during menses occurs in >90% of women. In susceptible individuals, defective peritoneal immunosurveillance allows ectopic tissue implantation.
Coelomic Metaplasia: Transformation of pluripotent peritoneal mesothelial cells into functional endometrial-like glandular tissue under chronic inflammatory, hormonal, or environmental stimuli.
Vascular & Lymphatic Dissemination (Halban's Theory): Transport of endometrial cells through pelvic venous channels and lymphatics, explaining distant extra-pelvic locations (pleura, umbilicus, surgical scars).
Immune Clearance Dysfunction & Local Steroidogenesis: Impaired natural killer (NK) cell cytotoxicity and defective macrophage phagocytosis fail to clear ectopic debris. Ectopic implants express high levels of aromatase , producing continuous local estradiol that drives chronic neurogenic inflammation, cytokine upregulation (IL-1, IL-6, TNF-alpha, VEGF), angiogenesis, and progressive fibrosis.
Classic Clinical Presentation
Endometriosis is classically characterized by the "4 Ds" :
Dysmenorrhea: Severe, secondary, crampy pelvic pain that typically begins several days prior to menses , worsens throughout flow, and responds poorly to over-the-counter analgesics.
Dyspareunia: Deep pelvic pain during or following penetrative vaginal intercourse, resulting from stretching of scarred uterosacral ligaments or the obliterated pouch of Douglas.
Dyschezia: Painful defecation, often cyclic and worsening during menstrual flow, reflecting rectovaginal or rectosigmoid peritoneal involvement.
Dysuria: Cyclic burning, urgency, or bladder pain during menses without documented bacterial infection.
Additional Manifestations: Chronic non-cyclic pelvic pain (>6 months), cyclic catamenial gastrointestinal symptoms (bloating, diarrhea, constipation), and subfertility or infertility (present in 30% to 50% of affected women).
[!CRITICAL] AMCB Clinical Pearl — Lack of Stage Correlation: The revised American Society for Reproductive Medicine (rASRM) staging system (Stage I: Minimal, Stage II: Mild, Stage III: Moderate, Stage IV: Severe) is based solely on anatomical lesion distribution and adhesive extent. The laparoscopic stage does NOT correlate with the severity of pain symptoms or disability. A patient with minimal peritoneal implants (Stage I) may suffer excruciating, disabling pain, while a woman with extensive frozen pelvis and bilateral large endometriomas (Stage IV) may be completely asymptomatic.
Physical Examination & Diagnostic Evaluation
Physical Exam Findings: Bimanual and rectovaginal examination may demonstrate palpable tender nodularity along the uterosacral ligaments , induration of the cul-de-sac (pouch of Douglas), a fixed, retroverted, immobile uterus (secondary to posterior pelvic dense adhesions), and tender, enlarged, fixed adnexal masses ( endometriomas ).
Transvaginal Ultrasound (TVUS): First-line imaging modality. TVUS is highly sensitive for detecting ovarian endometriomas ("chocolate cysts"), which characteristically appear as unilocular or multilocular cystic lesions with homogeneous, low-level internal echoes ("ground-glass" appearance) and absent vascular flow on color Doppler. Normal ultrasound does NOT rule out peritoneal endometriosis.
Definitive Gold Standard Diagnosis: Direct visualization via diagnostic laparoscopy with histologic confirmation of endometrial glands and stroma. However, current clinical guidelines strongly endorse initiating empiric medical therapy without requiring prior surgical laparoscopy in patients with a suggestive clinical history. Stepwise Medical Management Cascade for Endometriosis
- ├── First-Line Empiric Medical Therapy (Initiate without laparoscopy)
- │ ├── 1. Scheduled NSAIDs (Naproxen 500 mg BID or Ibuprofen 800 mg TID)
- │ └── 2. Continuous Hormonal Suppression
- │ ├── Combined Oral Contraceptives (continuous active pills without placebo)
- │ ├── Norethindrone Acetate (Aygestin, 5 to 15 mg PO daily)
- │ ├── Depot Medroxyprogesterone Acetate (DMPA, 150 mg IM q13w)
- │ └── 52 mg Levonorgestrel IUD (Mirena - profound local decidualization)
- └── Second-Line Medical Therapy (Refractory to first-line agents)
- ├── GnRH Agonists (Leuprolide acetate 3.75 mg IM monthly or 11.25 mg q3m)
- │ └── MANDATORY: Norethindrone acetate 5 mg/day "Add-Back" therapy
- └── Oral GnRH Antagonists (Elagolix 150 mg daily or 200 mg BID)
- └── Suppresses pituitary gonadotropins; dose-dependent estrogen suppression
Surgical Management: Indicated for severe intractable pain refractory to medical therapy, advanced deep infiltrating endometriosis affecting bowel or ureters, large endometriomas (>3 to 4 cm), or treatment of endometriosis-associated infertility. Involves laparoscopic excision or ablation of implants and endometrioma cystectomy (stripping the cyst wall rather than drainage/cautery to reduce recurrence and preserve ovarian reserve).
Adenomyosis: Clinical Recognition & Management
Adenomyosis is a benign uterine disorder characterized by the presence of heterotopic endometrial glands and stroma embedded within the myometrium , surrounded by reactive compensatory myometrial smooth muscle hyperplasia and hypertrophy .
Clinical Features & Demographics
Epidemiology: Most commonly diagnosed in multiparous women in their late 30s and 40s (40 to 50 years) ; associated with parity and prior uterine surgery (cesarean delivery, endometrial curettage).
Symptom Profile: Heavy menstrual bleeding (menorrhagia / HMB) in ~60% of cases (due to increased uterine cavity surface area, altered myometrial vascular architecture, and impaired myometrial contractility), severe secondary dysmenorrhea in ~30%, chronic dull pelvic aching, and deep dyspareunia. Approximately one-third of women are asymptomatic.
Physical Examination Findings: Bimanual examination reveals a symmetrically enlarged, soft, boggy, globally tender "globular" uterus , typically 10 to 14 weeks gestational size. Critically, unlike the fixed, retroverted uterus of endometriosis, the adenomyotic uterus is freely mobile .
Diagnostic Modalities & Treatment
Transvaginal Ultrasound (TVUS): First-line imaging. Diagnostic criteria include: asymmetrical myometrial thickening (predominantly posterior wall), subendometrial myometrial cysts (hypoechoic lacunae representing cystic dilatation of ectopic glands), subendometrial echogenic linear striations ("rain on a lake" / fan-shaped acoustic shadowing), and indistinct or disrupted endometrial-myometrial junctional zone (JZ).
Magnetic Resonance Imaging (MRI): Highly accurate. A thickened junctional zone ≥12 mm on T2-weighted MRI is diagnostic of adenomyosis (normal JZ is <8 mm).
Clinical Management:
First-Line Medical Therapy: 52 mg Levonorgestrel IUD (Mirena) is the most effective medical treatment; local intrauterine progestin release produces profound decidualization and endometrial atrophy, reducing menstrual blood loss by >70% to 90% and alleviating dysmenorrhea. Alternative medical options include continuous oral progestins, DMPA, or tranexamic acid/NSAIDs during menses.
Definitive Surgical Therapy: Total hysterectomy (with ovarian preservation) provides complete definitive cure for women who have completed childbearing and fail medical management.